Following the publication of the Perspective by Nirupama Sabnis and Andras G Lacko ‘Drug delivery via lipoprotein-based carriers: answering the challenges in systemic therapeutics‘ in the May 2012 issue of Therapeutic Delivery (Therapeutic Delivery 3[5], 599–608 [2012]), it has been brought to our attention that the following sections were incorrectly printed as:
“HDL: Class of lipoprotein that possesses the highest density as well as the greatest protein-to-lipid ratio and smallest diameter (8–10 nm). ApoA-I, A-II or E provides stabilization to the lipoprotein; encompassing either a discoidal lipid configuration or aspherical lipid shell with a hydrophobic, cholesterol ester interior.”
“These data strongly suggest that HDL-mimicking peptide–phospholipid nanoscaffolds can attenuate toxicity of anticancer drugs to nonmalignanent cells, thus resulting in selective cytotoxicity towards cancer cells.”
7 Chekman IS, Ulberg ZR, Gorchakova NO et al. The prospects of medical application of metal-basednanoparticles and nanomaterials. Lik. Sprava. 1–2, 3–21 (2011).
16 Elnaggar YS, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipidnanoparticles. Int. J. Nanomed. 6, 3195–3205 (2011).
17 Wang JJ, Zeng ZW, Xiao RZ et al. Recent advances of chitosannanoparticles as drug carriers. Int. J. Nanomed. 6, 765–774 (2011).
27 Bricarello DA, Smilowitz JT, Zivkovic AM, German JB, Parikh AN. Reconstituted lipoprotein: a versatile class of biologicallyinspired nanostructures. ACS Nano. 5(1), 42–57 (2011).
76 Banerjee S, Huber T, Sakmar TP. Rapidincorporationof functionalrhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles. J. Mol Biol. 377(4), 1067–1081 (2008).
The sections should have appeared as:
“HDL: Class of lipoprotein that possesses the highest density as well as the greatest protein-to-lipid ratio and smallest diameter (8–10 nm). ApoA-I, A-II or E provides stabilization to the lipoprotein; encompassing either a discoidal lipid configuration or a spherical lipid shell with a hydrophobic, cholesterol ester interior.”
“These studies strongly suggest that HDL-mimicking peptide–phospholipid nanoscaffolds can attenuate toxicity of anticancer drugs to nonmalignant cells, thus resulting in selective cytotoxicity towards cancer cells.”
7 Chekman IS, Ulberg ZR, Gorchakova NO et al. The prospects of medical application of metal-based nanoparticles and nanomaterials. Lik. Sprava. 1–2, 3–21 (2011).
16 Elnaggar YS, El-Massik MA, Abdallah OY. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int. J. Nanomed. 6, 3195–3205 (2011).
17 Wang JJ, Zeng ZW, Xiao RZ et al. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomed. 6, 765–774 (2011).
27 Bricarello DA, Smilowitz JT, Zivkovic AM, German JB, Parikh AN. Reconstituted lipoprotein: a versatile class of biologically inspired nanostructures. ACS Nano. 5(1), 42–57 (2011).
76 Banerjee S, Huber T, Sakmar TP. Rapid incorporation of functional rhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles. J. Mol Biol. 377(4), 1067–1081 (2008).
The authors and editors of Therapeutic Delivery would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.